Can heparin be discontinued after Percutaneous Coronary Intervention (PCI) and is there any reason to continue it in patients started on dual antiplatelet therapy (DAPT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Heparin Be Discontinued After PCI?

Yes, heparin should be discontinued immediately after uncomplicated PCI in patients started on dual antiplatelet therapy (DAPT). 1

Standard Post-PCI Anticoagulation Management

Discontinue parenteral anticoagulation immediately after the invasive procedure unless specific clinical indications exist for continued anticoagulation. 2 The ACC/AHA guidelines explicitly recommend stopping anticoagulant therapy after PCI for uncomplicated cases (Level of Evidence: B). 1

Why Heparin Should Be Stopped

  • Post-PCI heparin increases bleeding risk without cardiovascular benefit. The most recent high-quality evidence from the STOPDAPT-3 trial (2024) demonstrated that post-PCI heparin was associated with significantly increased bleeding (4.75% vs 2.52%, adjusted HR 1.69, p=0.007) and a numerically increased risk of cardiovascular events (3.16% vs 1.72%, adjusted HR 1.56, p=0.06). 3

  • Higher heparin doses correlate with worse outcomes. Both higher hourly doses and total doses of heparin were associated with increased incidence of bleeding and cardiovascular events within 30 days. 3

  • DAPT provides adequate antithrombotic protection. After successful PCI, the focus shifts to DAPT (aspirin plus P2Y12 inhibitor), which provides sufficient protection against stent thrombosis and ischemic events. 1, 4

Post-PCI Antithrombotic Strategy

Immediate Post-PCI Period

  • Continue aspirin indefinitely (75-100 mg daily). 4

  • Administer P2Y12 inhibitor loading dose if not given before diagnostic angiography:

    • Ticagrelor 180 mg loading dose, then 90 mg twice daily (preferred first-line) 4
    • Prasugrel 60 mg loading dose, then 10 mg daily (alternative first-line) 4
    • Clopidogrel 600 mg loading dose, then 75 mg daily (for high bleeding risk or patients requiring oral anticoagulation) 4

DAPT Duration

  • For acute coronary syndrome: Continue DAPT for 12 months regardless of stent type. 2, 4

  • For stable coronary disease: Continue DAPT for minimum 6 months after drug-eluting stent implantation. 4

  • For high bleeding risk patients (PRECISE-DAPT ≥25): Consider discontinuing P2Y12 inhibitor at 6 months. 2

Specific Indications for Continued Anticoagulation

When Heparin May Be Continued (Rare Situations)

The golden rule is to avoid continuing antithrombins after PCI except in specific individual situations such as thrombotic complications during the procedure. 2

If continued anticoagulation is required for specific clinical indications:

  • Subcutaneous unfractionated heparin provides a safer and less costly option than intravenous heparin for extending antithrombin therapy. 1

  • Resume oral anticoagulation within 24 hours after PCI in most patients requiring long-term anticoagulation, after assessing hemostasis at the access site. 1, 5

Patients Requiring Long-Term Oral Anticoagulation

For patients with atrial fibrillation or other indications for chronic anticoagulation:

  • Administer aspirin plus clopidogrel during the immediate peri-PCI phase through hospital discharge. 4, 5

  • Discontinue aspirin at hospital discharge or within 1 week and transition to double therapy (oral anticoagulant + clopidogrel 75 mg daily). 4, 5

  • Prefer a direct oral anticoagulant (DOAC) over warfarin at established stroke prevention doses. 4, 5

  • Continue P2Y12 inhibitor for 6-12 months depending on ischemic and bleeding risk, then discontinue antiplatelet therapy and continue oral anticoagulation alone. 6

Critical Pitfalls to Avoid

  • Never crossover between UFH and low molecular weight heparin (LMWH) as this significantly increases bleeding risk. 2, 1

  • Do not use bridging anticoagulation routinely in patients on DOACs—bridging is not recommended. 2

  • For patients on fondaparinux pre-PCI, give a single bolus of UFH (85 IU/kg, or 60 IU/kg with concomitant GP IIb/IIIa inhibitors) during the procedure, then discontinue. 2

  • Assess access site hemostasis carefully before restarting any anticoagulation, considering patient factors including recent bleeding history, body habitus, and platelet abnormalities. 1

References

Guideline

Heparin Infusion After PCI

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Antiplatelet Therapy Post-PCI

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Antithrombotic Therapy After PCI

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended anticoagulation regimen for patients undergoing Percutaneous Coronary Intervention (PCI)?
What is the recommended antiplatelet therapy for patients with a history of Percutaneous Coronary Intervention (PCI)?
What is the recommended dose of apixaban for a patient with Non-ST-Elevation Myocardial Infarction (NSTEMI) post-PerCutaneous Coronary Intervention (PCI) requiring anticoagulation?
What is the preferred combination of anticoagulant and antiplatelet therapy for a patient with atrial fibrillation (not valvular in origin) and a recent coronary stent, comparing Eliquis (apixaban) with Aspirin versus Eliquis (apixaban) with Plavix (clopidogrel)?
What is the most appropriate antithrombotic therapy for a 54-year-old man with atrial fibrillation (AF) who has undergone percutaneous coronary intervention (PCI) with a second-generation drug-eluting stent (DES) and has a low bleeding risk compared to the risk of stent thrombosis?
Why is it necessary to discontinue propranolol (a non-selective beta-blocker) and switch to verapamil (a calcium channel blocker) for managing hypertension in a 51-year-old male patient with bronchial asthma and a history of mild hypertension?
What is the management approach for a patient experiencing palpitations, with or without a history of anxiety or cardiac conditions?
What is the recommended waiting period before administering Venofer (iron sucrose) to a patient with a history of anemia, particularly those with chronic kidney disease, after a blood transfusion?
What is the recommended antibiotic course for the treatment of gonorrhea (Gono) and chlamydia?
What laboratory tests are recommended for a patient experiencing hot flashes?
What are the signs and symptoms of adrenal crisis in a patient with adrenal insufficiency?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.